Author information:
(1)From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College 
(A.D., E.R.) and New York University Langone Medical Center (V.V.), New York, 
and Roswell Park Comprehensive Cancer Center, Buffalo (G.K.D.) - all in New 
York; Dana-Farber Cancer Institute (G.R.O.) and Massachusetts General Hospital 
(J.G.), Boston; National Cancer Centre Singapore, Singapore (D.S.W.T.); the 
Chinese University of Hong Kong, Hong Kong, China (H.H.F.L.); Sarah Cannon 
Research Institute, Nashville (M.J.); University of California, San 
Francisco-Helen Diller Family Comprehensive Cancer Center, San Francisco 
(C.E.M.), University of California, San Diego, Moores Cancer Center, La Jolla 
(L.B.), and City of Hope Comprehensive Cancer Center, Duarte (K.L.R.) - all in 
California; University of Bern, Bern, and Cantonal Hospital of Lucerne, Lucerne 
- both in Switzerland (O.G.); Institut Gustave Roussy, Villejuif (B.B.), 
Hospital La Timone, Marseille (F.B.), and Centre Léon Bérard, Lyon (P.A.C.) - 
all in France; Severance Hospital, Yonsei University Health System (B.C.C.), and 
Samsung Medical Center, Sungkyunkwan University School of Medicine (K.P.), 
Seoul, and Seoul National University Bundang Hospital, Seongnam (Y.J.K.) - all 
in South Korea; Soroka University Medical Center, Beer-Sheva, Israel (N.P.); 
University of North Carolina-Chapel Hill, Chapel Hill (J. Weiss); National 
Cancer Center Hospital (Y.O.) and Cancer Institute Hospital of the Japanese 
Foundation for Cancer Research (M. Nishio), Tokyo, National Hospital 
Organization Kyushu Cancer Center, Fukuoka (T. Seto), Tottori University 
Hospital, Tottori (T. Sakamoto), Hyogo Cancer Center, Akashi (M.S.), Okayama 
University Hospital, Okayama (K.O.), and National Cancer Center Hospital East, 
Chiba (K.G.) - all in Japan; University of Chicago, Chicago (J.P.); the Ohio 
State University Comprehensive Cancer Center, Columbus (M.H.S.), and Cleveland 
Clinic, Cleveland (N.A.P.); Istituto Nazionale Tumori-National Cancer Institute, 
Università degli Studi di Milano, Milan (F.D.B.); Vall d'Hebron Institute of 
Oncology, Hospital Universitario Vall d'Hebron, Barcelona (E.G.); Center for 
Integrated Oncology, University Hospital of Cologne, Cologne, Germany (J. Wolf); 
Peter MacCallum Cancer Institute, Melbourne, VIC, Australia (B.S.); Sarah Cannon 
Research Institute at HealthONE, Denver (G.F.); Loxo Oncology, Stamford, CT 
(K.E., M. Nguyen, B.N., E.Y.Z., L.Y., X.H., E.O., S.M.R.); and the University of 
Texas M.D. Anderson Cancer Center, Houston (V.S.).